|
Market Closed -
Other stock markets
|
Pre-market 07:44:03 | |||
| 10.79 EUR | +0.84% |
|
10.81 | +0.19% |
| 12-04 | Grifols achieves self-sufficiency in plasma-derived medicines in Egypt | RE |
| 12-03 | European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading | MT |
Business description: Grifols, S.A.
- products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (2.9%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
Number of employees: 23,800
Sales by Activity: Grifols, S.A.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Biopharma | 4.24B | 3.81B | 5.01B | 5.56B | 6.14B |
Bio Supplies | 224M | 226M | 146M | 160M | 216M |
Diagnostic | 776M | 779M | 671M | 670M | 645M |
Others | 31.99M | 39.62M | 250M | 203M | 209M |
Intersegments | -53.11M | -67.55M | -8.95M | - | - |
Hospital | 119M | 141M | - | - | - |
Geographical breakdown of sales: Grifols, S.A.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States + Canada | 3.6B | 3.15B | 3.86B | 3.9B | 4.09B |
Rest of the World | 906M | 872M | 1.18B | 1.44B | 1.58B |
Rest of European Union | 495M | 544M | 712M | 893M | 1.12B |
Spain | 339M | 362M | 321M | 363M | 423M |
Executive Committee: Grifols, S.A.
| Manager | Title | Age | Since |
|---|---|---|---|
Nacho Abia
CEO | Chief Executive Officer | 57 | 31/03/2024 |
Jörg Schüttrumpf
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/08/2024 |
| Comptroller/Controller/Auditor | 46 | 31/12/2015 | |
| Corporate Officer/Principal | 55 | 31/12/2018 | |
David Bell
LAW | General Counsel | 71 | 30/06/2003 |
Composition of the Board of Directors: Grifols, S.A.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 24/01/2010 | |
| Director/Board Member | 69 | 12/04/2000 | |
| Director/Board Member | 62 | 23/05/2015 | |
| Director/Board Member | 49 | 26/05/2016 | |
| Director/Board Member | 60 | 23/05/2019 | |
| Director/Board Member | 57 | 09/06/2022 | |
| Director/Board Member | 48 | 09/06/2022 | |
Albert Coma-Cros
BRD | Director/Board Member | 47 | 18/12/2023 |
| Director/Board Member | 60 | 28/05/2015 | |
Nacho Abia
BRD | Director/Board Member | 57 | 25/02/2024 |
Holdings: Grifols, S.A.
| Name | Equities | % | Valuation |
|---|---|---|---|
| 437,069,656 | 6.49% | 409,333,216 $ |
Company details: Grifols, S.A.

Group companies: Grifols, S.A.
| Name | Category and Sector |
|---|---|
Gri-Cel SA
Gri-Cel SA Provides investment services | |
Grifols India Healthcare Pvt Ltd. | |
Grifols India Healthcare Pvt Ltd. |
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.84% | +0.37% | +15.35% | -0.32% | 7.73B | ||
| -0.74% | +3.19% | +1.37% | -1.16% | 76.06B | ||
| -2.51% | -3.34% | -35.22% | -39.66% | 58.92B | ||
| +1.38% | +69.20% | +69.20% | +69.20% | 53.01B | ||
| -2.24% | -4.93% | +30.25% | +215.42% | 52.48B | ||
| +0.93% | -3.97% | +16.04% | -39.77% | 25.54B | ||
| -4.75% | -5.14% | +124.00% | +150.23% | 18.76B | ||
| -0.72% | -6.94% | +39.18% | +15.41% | 18.73B | ||
| -4.52% | -5.15% | +36.59% | +998.98% | 15.67B | ||
| +1.46% | +2.05% | +173.37% | +686.91% | 14.48B | ||
| Average | -1.15% | -1.93% | +47.01% | +205.52% | 34.14B | |
| Weighted average by Cap. | -1.10% | -0.70% | +29.17% | +117.88% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GRF Stock
- Company Grifols, S.A.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
















